At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Vedolizumab SC +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open Label, Randomized, Parallel Group Study to Assess the Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
In Brief
A Phase 1 clinical trial evaluating Vedolizumab SC and Vedolizumab IV for Healthy. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the absolute bioavailability and pharmacokinetics of vedolizumab following a single injection of vedolizumab subcutaneously at 3 varying doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionDec 2014
Study CompletionJan 2015
TodayJul 2026
First PostedJun 13, 2014
Enrollment StartJun 1, 2014
Primary CompletionDec 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.1 years ago
Interventions
Vedolizumab SCdrug
Vedolizumab injection, for subcutaneous use (vedolizumab SC)
Vedolizumab IVdrug
Vedolizumab injection, for intravenous use (vedolizumab IV)